• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques.

作者信息

Liu Xiaolei, Liu Yi, Jin Xuemin, He Zhanlong, Huang Zhen, Sun Shumin, Gao Yuwei, Li Jingyu, Ning Qin, Xie Zhongping, Jin Ningyi, Liu Mingyuan

机构信息

State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, 130062, Changchun, China.

Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, 650118, Kunming, China.

出版信息

Signal Transduct Target Ther. 2022 Jul 7;7(1):219. doi: 10.1038/s41392-022-01095-8.

DOI:10.1038/s41392-022-01095-8
PMID:35798694
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9261890/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/9263160/1fbb4b514909/41392_2022_1095_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/9263160/1fbb4b514909/41392_2022_1095_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f6/9263160/1fbb4b514909/41392_2022_1095_Fig1_HTML.jpg

相似文献

1
Rapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques.针对恒河猴中SARS-CoV-2感染的可快速研发的治疗级马免疫球蛋白。
Signal Transduct Target Ther. 2022 Jul 7;7(1):219. doi: 10.1038/s41392-022-01095-8.
2
Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques.基于单剂量腺相关病毒的疫苗在恒河猴体内诱导产生高水平的抗SARS-CoV-2中和抗体。
Protein Cell. 2022 Jul 15;14(1):69-73. doi: 10.1093/procel/pwac020. eCollection 2023 Jan.
3
Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques.德尔塔（B.1.617.2）灭活疫苗候选物在恒河猴中诱导出针对 SARS-CoV-2 和循环变异株的中和抗体。
Virol Sin. 2023 Aug;38(4):627-630. doi: 10.1016/j.virs.2023.05.009. Epub 2023 May 25.
4
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
5
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.恒河猴初次接触 SARS-CoV-2 可预防再次感染。
Science. 2020 Aug 14;369(6505):818-823. doi: 10.1126/science.abc5343. Epub 2020 Jul 2.
6
[Clinical progress of neutralizing antibodies against SARS-CoV-2].[新型冠状病毒2型中和抗体的临床进展]
Sheng Wu Gong Cheng Xue Bao. 2022 Jun 25;38(6):2061-2068. doi: 10.13345/j.cjb.220118.
7
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques.基于衣壳病毒样颗粒的 SARS-CoV-2 疫苗可诱导高水平抗体并保护恒河猴。
Front Immunol. 2022 Apr 5;13:857440. doi: 10.3389/fimmu.2022.857440. eCollection 2022.
8
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.SARS-CoV-2 感染可使恒河猴免受再次感染。
Science. 2020 Aug 14;369(6505):812-817. doi: 10.1126/science.abc4776. Epub 2020 May 20.
9
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model.皮内递送 DNA 疫苗可诱导持久免疫，介导恒河猴 SARS-CoV-2 挑战模型中病毒载量的降低。
Cell Rep Med. 2021 Oct 19;2(10):100420. doi: 10.1016/j.xcrm.2021.100420. Epub 2021 Sep 28.
10
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.康复期新冠患者和接受RBD纳米颗粒疫苗接种的恒河猴的血清对新型突变体B.1.1.7和501Y.V2的中和效率差异。
Cell Mol Immunol. 2021 Apr;18(4):1058-1060. doi: 10.1038/s41423-021-00641-8. Epub 2021 Feb 12.

本文引用的文献

1
RBD-specific polyclonal F(ab´) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.中度至重度新冠肺炎患者中马源抗体的RBD特异性多克隆F(ab´)片段：一项随机、多中心、双盲、安慰剂对照的适应性2/3期临床试验。
EClinicalMedicine. 2021 Apr;34:100843. doi: 10.1016/j.eclinm.2021.100843. Epub 2021 Apr 11.
2
Immunoglobulin fragment F(ab') against RBD potently neutralizes SARS-CoV-2 in vitro.针对 RBD 的免疫球蛋白 F(ab') 片段在体外有力地中和了 SARS-CoV-2。
Antiviral Res. 2020 Oct;182:104868. doi: 10.1016/j.antiviral.2020.104868. Epub 2020 Jul 10.
3
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
4
Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.异种抗血清和抗蛇毒血清是重要的生物制品：关于全球危机的观点。
Ann Intern Med. 1996 Aug 1;125(3):233-6. doi: 10.7326/0003-4819-125-3-199608010-00012.